PURPOSE: Cerebral vasospasm (CVS) is a frequent and unpredictable complication in patients with subarachnoid hemorrhage (SAH) and often leads to poor outcomes. This study was aimed at evaluating the efficacy and safety of fasudil in the treatment of CVS in patients with SAH. METHODS: A search was conducted using the full-text database of Chinese scientific journals, the Wanfang Database (January 1999 to November 2010), the Chinese Medical Association Digital Journal Database, PubMed, the Cochrane library, OVID, and EMBase (searching through November 2010). RESULTS: A total of 8 studies met the inclusion criteria. The incidence rates of symptomatic CVS and CVS confirmed by angiography among the patients in the fasudil group were only 48% (odds ratio [OR] = 0.48, 95% confidence interval [CI]: 0.32-0.72, P = 0.0005) and 40% (OR = 0.40, 95% CI: 0.24-0-67, P = 0.0004) respectively of that of the control group. The odds ratios of cerebral infarction for all cases and cerebral infarction for CVS cases in the fasudil group were only 50% (OR = 0.50, 95% CI: 0.34-0.76, P = 0.0009) and 43% (OR = 0.43, 95% CI: 0.26-0.70, P = 0.0008) respectively of that of the control group. CONCLUSIONS: Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAH patients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale). Because of the limited number of trials and samples available for analysis, the conclusions from the present study still need to be validated with results from large randomized, controlled clinical trials.
PURPOSE:Cerebral vasospasm (CVS) is a frequent and unpredictable complication in patients with subarachnoid hemorrhage (SAH) and often leads to poor outcomes. This study was aimed at evaluating the efficacy and safety of fasudil in the treatment of CVS in patients with SAH. METHODS: A search was conducted using the full-text database of Chinese scientific journals, the Wanfang Database (January 1999 to November 2010), the Chinese Medical Association Digital Journal Database, PubMed, the Cochrane library, OVID, and EMBase (searching through November 2010). RESULTS: A total of 8 studies met the inclusion criteria. The incidence rates of symptomatic CVS and CVS confirmed by angiography among the patients in the fasudil group were only 48% (odds ratio [OR] = 0.48, 95% confidence interval [CI]: 0.32-0.72, P = 0.0005) and 40% (OR = 0.40, 95% CI: 0.24-0-67, P = 0.0004) respectively of that of the control group. The odds ratios of cerebral infarction for all cases and cerebral infarction for CVS cases in the fasudil group were only 50% (OR = 0.50, 95% CI: 0.34-0.76, P = 0.0009) and 43% (OR = 0.43, 95% CI: 0.26-0.70, P = 0.0008) respectively of that of the control group. CONCLUSIONS:Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAHpatients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale). Because of the limited number of trials and samples available for analysis, the conclusions from the present study still need to be validated with results from large randomized, controlled clinical trials.
Authors: R Loch Macdonald; Randall T Higashida; Emanuela Keller; Stephan A Mayer; Andy Molyneux; Andreas Raabe; Peter Vajkoczy; Isabel Wanke; Aline Frey; Angelina Marr; Sébastien Roux; Neal F Kassell Journal: Neurocrit Care Date: 2010-12 Impact factor: 3.210
Authors: M Shibuya; Y Suzuki; K Sugita; I Saito; T Sasaki; K Takakura; I Nagata; H Kikuchi; T Takemae; H Hidaka Journal: J Neurosurg Date: 1992-04 Impact factor: 5.115
Authors: Marike Zwienenberg-Lee; Jonathan Hartman; Nancy Rudisill; Lori Kennedy Madden; Karen Smith; Joseph Eskridge; David Newell; Bon Verweij; M Ross Bullock; Andrew Baker; William Coplin; Robert Mericle; Jian Dai; David Rocke; J Paul Muizelaar Journal: Stroke Date: 2008-04-17 Impact factor: 7.914
Authors: Basem M William; Wei An; Dan Feng; Scott Nadeau; Bhopal C Mohapatra; Matthew A Storck; Vimla Band; Hamid Band Journal: Hematology Date: 2015-07-15 Impact factor: 2.269
Authors: Kyle R Covington; Lauren Brusco; Ines Barone; Anna Tsimelzon; Jennifer Selever; Arnoldo Corona-Rodriguez; Powel Brown; Rakesh Kumar; Susan G Hilsenbeck; Suzanne A W Fuqua Journal: Breast Cancer Res Treat Date: 2013-09-28 Impact factor: 4.872
Authors: Anuska V Andjelkovic; Jianming Xiang; Svetlana M Stamatovic; Ya Hua; Guohua Xi; Michael M Wang; Richard F Keep Journal: Arterioscler Thromb Vasc Biol Date: 2019-09-12 Impact factor: 8.311